2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Omics Technologies, Emerging Technologies, Gene Editing, Treatment Considerations, Combination Therapy, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Pathogenesis, Immune Mechanism, Multi-Systemic Interactions, Diseases, Immunology, Autoimmune Disorders, Immunodeficiency, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, ALL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

2409 Durable remissions induced by IL18-armored anti-CD19 CAR T cells (huCART19-IL18) in patients with B-cell non-Hodgkin lymphomas after prior anti-CD19 CAR T-cell failure

Jakub Svoboda, MD, Daniel Landsburg, MD2, Sunita Dwivedy Nasta, MD, MS3, Stefan K Barta, MD4, Elise A. Chong, MD5, Michael R Cook, MD6, Jordan S Carter, MD7, Colin J. Thomas, MD8, Emily B. Tomasulo, DO9, Noelle Frey, MD, MSCE10, Joanne Shea11, Charles W. Tongue12, Jean McConville13, Rutendo Manyeka14, Megan Four15, Amy Marshall16, Anne Chew17, Cory Czuczman, MPH18, Luca Paruzzo, MD19, Juliana Rojas Levine20, Donald Hasenmayer21, Gabriela Plesa, MD, PhD22, Don Siegel, MD PhD23, Vanessa Gonzalez24, Julie Jadlowsky25, Rachel Leskowitz26, Shannon Christensen, PhD27, Marco Ruella, MD28, Joseph Fraietta, PhD29, Bruce L Levine, PhD30, David Porter, MD31, Wei-Ting Hwang, PhD32, Stephen J Schuster33, Elizabeth Hexner, MD34, Carl H. June Jr, MD35
1 University of Pennsylvania, Philadelphia, United States
2 University of Pennsylvania, Philadelphia, United States
3 University of Pennsylvania, Philadelphia, United States
4 University of Pennsylvania, Philadelphia, United States
5 University of Pennsylvania, Philadelphia, United States
6 University of Pennsylvania, Philadelphia, United States
7 University of Pennsylvania, Philadelphia, United States
8 University of Pennsylvania, Philadelphia, United States
9 University of Pennsylvania, Philadelphia, United States
10 University of Pennsylvania, Philadelphia, United States
11 University of Pennsylvania, Philadelphia, United States
12 University of Pennsylvania, Philadelphia, United States
13 University of Pennsylvania, Philadelphia, United States
14 University of Pennsylvania, Philadelphia, United States
15 University of Pennsylvania, Philadelphia, United States
16 University of Pennsylvania, Philadelphia, United States
17 University of Pennsylvania, Philadelphia, United States
18 University of Pennsylvania, Philadelphia, United States
19 University of Pennsylvania, Philadelphia, United States
20 University of Pennsylvania, Philadelphia, United States
21 University of Pennsylvania, Philadelphia, United States
22 University of Pennsylvania, Philadelphia, United States
23 University of Pennsylvania, Philadelphia, United States
24 University of Pennsylvania, Philadelphia, United States
25 University of Pennsylvania, Philadelphia, United States
26 University of Pennsylvania, Philadelphia, United States
27 University of Pennsylvania, Philadelphia, United States
28 University of Pennsylvania, Philadelphia, United States
29 University of Pennsylvania, Philadelphia, United States
30 University of Pennsylvania, Philadelphia, United States
31 University of Pennsylvania, Philadelphia, United States
32 University of Pennsylvania, Philadelphia, United States
33 University of Pennsylvania, Philadelphia, United States
34 University of Pennsylvania, Philadelphia, United States
35 University of Pennsylvania, Philadelphia, United States

Introduction: Patients with B-cell non-Hodgkin lymphomas (NHL) who progress after receiving FDA-approved anti-CD19 CAR T-cell therapy have few potentially curative treatment options. We previously reported initial results from the first-in-human study of huCART19-IL18, an interleukin-18 (IL18)-armored anti-CD19 CAR T-cell product, in heavily pretreated patients with relapsed/refractory B-cell NHL (Svoboda et al., NEJM 2025). We now report long-term follow-up focused on the durability of benefit from huCART19-IL18 in patients with prior anti-CD19 CAR T-cell failure.

Methods: We performed a long-term follow-up analysis of patients with CD19-positive B-cell lymphomas treated with huCART19-IL18 in the phase I trial (NCT04684563). Study design, expedited 3-day manufacturing, dose levels, and patient eligibility were previously published as noted above. During the primary follow-up period, patients were assessed for response every 3 months for 1 year after huCART19-IL18 infusion. Patients who remained progression-free subsequently entered long-term follow-up, with disease assessments performed every 6-12 months or more frequently at the investigator's discretion. Patients who initially derived clinical benefit from huCART19-IL18 were eligible for retreatment. Progression-free survival (PFS) and overall survival (OS) were calculated from huCART19-IL18 infusion.

Results: Twenty-one patients with NHL were treated with huCART19-IL18. Median age was 64 years (range, 47-74), and 16 (76%) were male. Histologies included large B-cell lymphoma (LBCL; n=12, 57%), follicular lymphoma (FL; n=6, 29%), and mantle cell lymphoma (MCL; n=3, 14%). Twenty patients (95%) had previously received conventional anti-CD19 CAR T-cell therapy. At 3 months after the initial infusion of huCART19-IL18, the overall response rate was 81% (95% CI, 58%-95%) with complete response in 52% (95% CI, 30%-74%). At the data cutoff (April 1, 2026), the reverse Kaplan-Meier median follow-up was 43 months (95% CI, 34.3-51.5). Median PFS was 9.4 months (95% CI, 5.4-not estimable [NE]) and median duration of response (DOR) was 9.6 months (95% CI, 2.8-NE). The estimated 3-year PFS and DOR rates were 41% (95% CI, 19%-62%) and 46% (95% CI, 19%-70%), respectively. Median OS was not reached (95% CI, 31.2 months-NE), with an estimated 3-year OS of 74% (95% CI, 49%-89%). Nine patients (45%) remain progression-free at the data cutoff, including three patients (two LBCL and one FL) with ongoing remissions exceeding 4 years. Among the 20 patients previously treated with conventional anti-CD19 CAR T-cell therapy, 13 (65%; 95% CI, 41%-85%) achieved a longer PFS with huCART19-IL18 than with their prior CAR T-cell therapy. Seven patients (33%) underwent retreatment with huCART19-IL18 at a median of 7.6 months (range, 3.9-35.6) after initial infusion. The overall response rate after retreatment was 71%, including complete responses in four patients. The estimated 3-year DOR after retreatment was 80% (95% CI, 20%-97%). No unexpected late toxicities were observed. Second primary malignancies occurred in four patients (19%), including basal cell carcinoma (n=1), squamous cell carcinoma of the neck (n=1), and myelodysplastic syndrome (n=2). Five patients (24%) died, including four from progressive lymphoma and one from pneumonia occurring more than 2 years after treatment. Four of nine patients with ongoing remission continue to receive IVIG for hypogammaglobulinemia. Correlative studies demonstrate prolonged huCART19-IL18 persistence, with detectable CAR T cells in peripheral blood beyond 30 months in six patients.

Conclusion: At a median follow-up of 43 months, huCART19-IL18 produced durable remissions in heavily pretreated patients with B-cell NHL. Notably, 65% of patients with prior CAR T-cell failure achieved longer progression-free survival with huCART19-IL18 than with their initial CAR T-cell therapy, and nearly half remain progression-free, with some remissions lasting beyond 4 years. Long-term safety remains favorable, and prolonged huCART19-IL18 persistence may contribute to sustained clinical benefit. These findings suggest that IL18-armored CAR T cells may overcome resistance to prior anti-CD19 CAR T-cell therapy and offer curative potential in a subset of patients, supporting further clinical development of cytokine-armored products.

Jakub Svoboda, MD: AstraZeneca - Research Funding; Kite, a Gilead Company - Research Funding; Pharmacyclics - Research Funding; Merck - Research Funding; Incyte - Research Funding; BMS - Research Funding; AstraZeneca - Consultancy (Includes expert testimony); Abbvie/Genentech - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Atara Biotherapeutics - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony)